Dr. Marty Makary has resigned from his position as the U.S. Food and Drug Administration (FDA) commissioner, effective Tuesday. This move comes after 13 months of tumultuous governance marked by internal disputes and external pressures, including potential dissatisfaction from President Trump’s administration.
Makary's departure follows reports that his tenure was marred by organizational upheaval and controversial drug approvals. His successor will be Kyle Diamantas, the agency’s deputy commissioner for food, who has been confirmed to serve as acting FDA commissioner effective immediately. The transition highlights a critical moment in regulatory leadership during a politically charged environment.
According to multiple sources, Makary's resignation was prompted by growing tensions within the administration and challenges he faced managing high-profile issues such as fruit-flavored vaping products. These factors contributed significantly to his decision to step down, leaving behind a complex legacy of policy decisions and organizational changes at the FDA.
The appointment of Diamantas underscores the continuity in leadership while signaling potential shifts ahead for agency priorities. As acting commissioner, Diamantas will navigate these challenges with the immediate task of maintaining stability and addressing pressing public health concerns, including ongoing issues related to drug approvals and regulatory oversight.
This change in leadership is expected to have broader implications for future policy decisions at the FDA, as new direction could be imminent under different administrative pressures.
This article was produced by AVALW News on Tuesday, May 12, 2026 based on reporting from 8 verified news sources. Our editorial process cross-references facts from multiple independent outlets to deliver accurate, comprehensive coverage. All original sources are linked below.